Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Stella Chemifa Corporation (4109.T)
Osaka, JP
Stella Chemifa Corporation, a Japanese company established in 1916 and headquartered in Osaka, specializes as a global manufacturer and supplier of inorganic fluorine compounds. Formerly known as Hashimoto Chemical Corporation until its rebranding in 1997, the company offers a comprehensive product portfolio tailored for diverse industrial applications worldwide. For the electronics sector, Stella Chemifa provides essential materials such as hydrofluoric acid, buffered hydrofluoric acid, and various etching solutions used in the production of semiconductors, liquid crystal displays, and solar cells. It also supplies a range of metal fluorides, including calcium, aluminum, and lithium fluoride, crucial for optical applications, alongside lithium hexafluorophosphate for battery manufacturing. Its offerings extend to numerous boron trifluoride compounds, serving as vital reactive catalysts across different chemical processes. Additionally, the company produces anhydrous hydrofluoric acid and 55% hydrofluoric acid, utilized in surface treatment and as more environmentally conscious alternatives to CFCs. Stella Chemifa also supports the nuclear energy industry with potassium fluoroborate and boric acid, and provides tin fluoride (II) USP for products requiring GMP compliance. Beyond these specialized compounds, the company's extensive catalog includes a broad array of other fluorochemicals, such as fluorosilicic acid, various fluorosilicates, fluoroboric acid, diverse fluoroborates, and a selection of ammonium, sodium, and potassium fluorides. Complementing its manufacturing operations, Stella Chemifa offers logistics services for the transportation of specialized chemical substances, high-pressure gases, and hazardous materials. Demonstrating a commitment to innovation, the company is also actively involved in the development of Boron Neutron Capture therapy for cancer treatment.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.50% | +12.24% | +25.68% | +21.23% | +58.20% | +47.62% | +78.36% | +135.10% | +121.65% | +132.00% | +40.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+1.4% Q1'26: +2.1% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+7.2% Q1'26: +308.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+7.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+12.6% ★ Q1'26: +10.8% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+8.3% ★ Q1'26: +7.6% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-1.4% ★ Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.74× ★ Q1'26: 0.74× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
28.34B
est: 28.00B (+1.2%)
|
27.51B
est: 27.63B (-0.5%)
|
29.85B
est: 29.30B (+1.9%)
|
33.62B
est: 33.50B (+0.4%)
|
38.38B
est: 38.60B (-0.6%)
|
33.73B
est: 32.35B (+4.3%)
|
32.89B
est: 33.35B (-1.4%)
|
37.30B
est: 37.00B (+0.8%)
|
35.38B
est: 35.80B (-1.2%)
|
30.45B
est: 31.90B (-4.6%)
|
36.29B
est: 35.88B (+1.1%)
|
36.10B
35.84B – 36.36B
+0.6% YoY
|
39.39B
39.00B – 39.78B
+9.1% YoY
|
41.80B
41.60B – 42.00B
+6.1% YoY
|
| EBITDA |
3.72B
est: 5.67B (-34.4%)
|
4.91B
est: 5.60B (-12.3%)
|
7.38B
est: 5.94B (+24.3%)
|
5.63B
est: 6.79B (-17.1%)
|
6.78B
est: 7.82B (-13.4%)
|
5.64B
est: 6.55B (-13.9%)
|
7.11B
est: 6.76B (+5.2%)
|
7.29B
est: 7.50B (-2.7%)
|
6.11B
est: 7.25B (-15.8%)
|
5.49B
est: 7.20B (-23.7%)
|
7.15B
est: 8.09B (-11.6%)
|
8.14B
8.08B – 8.20B
+0.6% YoY
|
8.89B
8.80B – 8.97B
+9.1% YoY
|
9.43B
9.38B – 9.47B
+6.1% YoY
|
| EBIT |
93.00M
est: 3.40B (-97.3%)
|
1.39B
est: 3.35B (-58.6%)
|
4.26B
est: 3.55B (+19.9%)
|
2.28B
est: 4.06B (-43.8%)
|
3.52B
est: 4.68B (-24.7%)
|
2.41B
est: 3.92B (-38.6%)
|
4.07B
est: 4.04B (+0.6%)
|
4.58B
est: 4.49B (+2.0%)
|
3.51B
est: 4.34B (-19.1%)
|
2.72B
est: 4.45B (-38.8%)
|
4.34B
est: 5.01B (-13.3%)
|
5.04B
5.00B – 5.07B
+0.6% YoY
|
5.50B
5.44B – 5.55B
+9.1% YoY
|
5.83B
5.81B – 5.86B
+6.1% YoY
|
| Net Income |
1.32B
est: 1.50B (-11.9%)
|
1.32B
est: 1.33B (-0.3%)
|
2.82B
est: 2.70B (+4.6%)
|
1.27B
est: 1.35B (-5.6%)
|
2.35B
est: 2.42B (-2.7%)
|
1.92B
est: 1.56B (+23.5%)
|
2.96B
est: 2.27B (+30.3%)
|
5.36B
est: 2.97B (+80.4%)
|
2.28B
est: 2.02B (+12.7%)
|
1.85B
est: 1.94B (-4.9%)
|
2.89B
est: 3.23B (-10.4%)
|
2.98B
2.95B – 3.01B
-7.7% YoY
|
3.24B
3.04B – 3.46B
+8.8% YoY
|
3.82B
3.50B – 4.16B
+17.9% YoY
|
| SGA |
2.68B
est: 2.78B (-3.6%)
|
2.22B
est: 2.74B (-19.1%)
|
2.55B
est: 2.91B (-12.2%)
|
2.74B
est: 3.32B (-17.6%)
|
2.84B
est: 3.83B (-25.8%)
|
2.77B
est: 3.21B (-13.9%)
|
3.34B
est: 3.31B (+0.9%)
|
3.57B
est: 3.67B (-2.7%)
|
3.24B
est: 3.55B (-8.9%)
|
3.03B
est: 3.10B (-2.2%)
|
3.32B
est: 3.48B (-4.6%)
|
3.50B
3.48B – 3.53B
+0.6% YoY
|
3.82B
3.78B – 3.86B
+9.1% YoY
|
4.06B
4.04B – 4.08B
+6.1% YoY
|
| EPS |
110.18
est: 125.00 (-11.9%)
|
110.26
est: 110.60 (-0.3%)
|
234.53
est: 225.00 (+4.2%)
|
100.45
est: 112.30 (-10.6%)
|
181.99
est: 201.30 (-9.6%)
|
149.00
est: 129.70 (+14.9%)
|
230.69
est: 189.25 (+21.9%)
|
422.93
est: 247.70 (+70.7%)
|
185.97
est: 168.55 (+10.3%)
|
153.44
est: 164.01 (-6.4%)
|
240.96
est: 272.75 (-11.7%)
|
251.75
249.39 – 254.11
-7.7% YoY
|
274.45
256.90 – 292.00
+9.0% YoY
|
323.60
296.00 – 351.20
+17.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.09% | 363.4K | 0.58% |
| 2 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.07% | 221.4K | 0.31% |
| 3 | WisdomTree Japan Hedged Equity Fund DXJ | 0.03% | 2.38M | 0.48% |
| 4 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 257.5K | 0.40% |
| 5 | WisdomTree International High Dividend Fund DTH | 0.03% | 185.1K | 0.58% |
| 6 | WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc DXJD.SW | 0.02% | 246.3K | 0.45% |
| 7 | WisdomTree Japan Equity UCITS ETF - GBP Hedged DXJP.L | 0.02% | 266.8K | 0.45% |
| 8 | WisdomTree Japan Equity UCITS ETF - USD Hedged Acc DXJA.L | 0.02% | 199.5K | 0.48% |
| 9 | WisdomTree Japan Equity UCITS ETF DXJ.L | 0.02% | 199.5K | 0.48% |
| 10 | WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc DXJF.MI | 0.02% | 227.3K | 0.45% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aki Hashimoto | Chief Executive Officer, President & Director | — | female |
| Jun Takano | Senior MD of Research & Development and Director | — | male |
| Kiyonori Saka | Executive Vice President of Products Management Group & Representative Director | — | male |
| Liu Shibu | Executive Officer | — | — |
| Masaaki Tsuchiya | Executive Officer, Manager of Sanpo Factory & Director | — | male |
| Miyuki Koike | Executive Officer & General Affairs Manager | — | — |
| Norio Ogata | Head of Sales Management Department, GM of Osaka Sales Department, Executive Officer & Director | — | male |
| Takeshi Iijima | Executive Officer - Singapore Region & Director | — | male |
| Yasuhiko Nakashima | Executive Officer, GM of Accounting Department & Director | — | male |
| Yoshiki Nakagawa | Executive Officer & Izumi Factory Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4109.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
